Erbitux, adagrasib combination shrinks tumors in 39 percent of colon cancer patients: Mirati Therapeutics

Published On 2021-09-20 04:45 GMT | Update On 2021-09-20 11:04 GMT

New Delhi: A combination of Mirati Therapeutics Inc's genetic mutation-targeting adagrasib and older cancer drug Erbitux shrank tumors in 39% of patients with advanced colorectal cancer treated in a small trial, the company said on Sunday.

Chief Executive Officer Charles Baum told Reuters Mirati plans to meet with the U.S. Food and Drug Administration in October to discuss whether it can pursue accelerated approval based on the combination therapy data.

Adagrasib targets a mutated form of a gene known as KRAS that occurs in around 13% of non-small cell lung cancers, 3% to 5% of colorectal cancers and up to 2% of other solid tumor cancers. Like other newer experimental drugs, it homes in on specific gene mutations driving cancer regardless of the organ in which the disease originated.

In May, Amgen Inc's Lumakras became the first approved drug in the class after the U.S. Food and Drug Administration cleared it for use in patients with advanced non-small cell lung cancer.

At a meeting of the European Society of Medical Oncology (ESMO) on Sunday, Mirati said that out of 28 evaluated trial patients treated with adagrasib plus Erbitux, 11, or 39%, experienced tumor shrinkage. Two patients had tumor growth, but the cancer was stabilized in the others, Mirati said.

Erbitux is an Eli Lilly & Co drug designed to block one of the signals that tells a tumor cell to grow by attaching to a structure on the cell called the epidermal growth factor receptor (EGFR).

At the ESMO meeting earlier this week, Amgen said a trial of Lumakras in combination with its own EGFR inhibitor Vectibix found that 7 out of 26 advanced colorectal cancer patients, or 27%, responded to the combination therapy.

Mirati said that at the time of its analysis, with a median follow up of seven months, 63% of enrolled patients remained on its combination treatment.

In a segment of the trial where colorectal cancer patients were given adagrasib alone, 22% of evaluated patients responded to the drug, the company said.

Researchers said serious side effects occurred in 30% of patients treated with adagrasib alone, and in 16% of patients treated with the combination. Two patients who received the combination discontinued treatment after developing infusion-related reactions.

"It looks like we've gained quite a bit in efficacy and not really added much significant toxicity. So that's why, you know, that combination approach may end up being our fastest approach for accelerated approval," CEO Baum said.

Mirati plans to present updated results from a trial of adagrasib for lung cancer patients at ESMO on Monday.

Both Amgen and Mirati are also studying their drugs in combination with Keytruda, Merck & Co's blockbuster immunotherapy, for treating lung cancer.

Read also: CoSara Diagnostics gets CDSCO clearance for chikungunya, dengue tests

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Erbitux, adagrasib combination shrinks tumors in 39 percent of colon cancer patients: Mirati Therapeutics

Similar News

GSK Shingrix approved by USFDA in prefilled syringe presentation

Novartis names Mukul Mehta as CFO

Sanofi India appoints Rachid Ayari as Interim MD

Zydus Matoda facility completes USFDA Remote Regulatory Assessment

Lupin rolls out Loteprednol Etabonate Ophthalmic Suspension, 0.5% in US

GSK blood cancer drug Blenrep faces USFDA scrutiny over vision issues

Expert Drug Panel Clears Proposal to Amend Licensing Forms for Advanced Biologics, Xenografts

First patient randomized in Ropanicant Phase 2b trial for Major Depressive Disorder: Suven Life Sciences